Lisata Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Lisata Therapeutics

02/11/2023 23:10

* Lisata Therapeutics Inc  LSTA.OQ  reported a quarterly
adjusted
loss of 65 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of $-7.88.  The mean expectation of two analysts
for the quarter was for a loss of 93 cents per share. Wall
Street expected results to range from -94 cents to -92 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Lisata Therapeutics Inc's reported EPS for the quarter was
a
loss of 65 cents​.
    * The company reported a quarterly loss of $5.26 million.
    * Lisata Therapeutics Inc shares had fallen by 0.9% this
quarter and lost 16.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Lisata
Therapeutics Inc is $15.00 
This summary was machine generated from LSEG data November 2 at
11:10 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.93          -0.65          Beat
 Jun. 30 2023      -0.70          -0.50          Beat
 Mar. 31 2023      -0.81          -0.77          Beat
 Dec. 31 2022      -1.01          -0.76          Beat